{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:27:08Z","timestamp":1794014828723,"version":"4.8.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Belatacept, a selective T-cell costimulation blocker, was associated with improved survival and renal function but also with a risk of posttransplant lymphoproliferative disorder (PTLD) in adult kidney transplant recipients in phase 3 trials. This registry examined long-term safety in Epstein\u2013Barr virus (EBV)\u2013seropositive kidney transplant recipients treated with belatacept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>This US-based, prospective, voluntary, multicenter registry (Evaluating Nulojix Long-Term Safety in Transplant [ENLiST]) included adult EBV-seropositive kidney-only transplant recipients treated de novo (within 14 d of transplantation) with belatacept. Primary objectives were to estimate incidence rates of confirmed PTLD, central nervous system (CNS) PTLD, and progressive multifocal encephalopathy (PML). The minimum follow-up was 2 y.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Of 985 enrolled transplant recipients, 933 EBV-seropositive patients received belatacept, with 523 (56.1%) receiving concomitant tacrolimus at transplant (for up to 12 mo). By study end, 3 cases of non-CNS PTLD (incidence rate, 0.08\/100 person-years), 1 case of CNS PTLD (0.03\/100 person-years), and no cases of PML had been reported. Two patients with non-CNS PTLD received concomitant belatacept and tacrolimus and 1 received belatacept and lymphocyte-depleting therapy. Incidence rates were comparable between patients who received concomitant belatacept and tacrolimus and those who did not receive tacrolimus (0.09\/100 person-years and 0.07\/100 person-years, respectively;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.96). Two of 4 patients with PTLD died, and 2 were alive at the end of the study. Cumulatively, 131 graft losses or deaths were reported by study end.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Our results from the ENLiST registry, a large, prospective real-world study, showed that the incidence rates of PTLD and CNS PTLD in belatacept-treated EBV-seropositive transplant recipients were consistent with findings from previous phase 3 trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/txd.0000000000001644","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:00:32Z","timestamp":1715997632000},"page":"e1644","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Long-term Safety in Epstein\u2013Barr Virus\u2013Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry"],"prefix":"10.1097","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-2649","authenticated-orcid":false,"given":"Christian P.","family":"Larsen","sequence":"first","affiliation":[{"name":"Department of Surgery, Emory University Transplant Center, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Vincenti","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Surgery, University of California, San Francisco, Transplant Center, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuyung","family":"D. Kou","sequence":"additional","affiliation":[{"name":"Worldwide Patient Safety, Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Shadur","sequence":"additional","affiliation":[{"name":"Transplantation Service, Iowa Kidney Physicians, Des Moines, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bresnahan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Cedars Sinai, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Steve","family":"Woodle","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Cincinnati, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Goes","sequence":"additional","affiliation":[{"name":"Kidney Transplant Clinics, Kaiser Permanente, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vella","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Transplantation, Maine Nephrology Associates, Portland, ME."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wojciechowski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Polinsky","sequence":"additional","affiliation":[{"name":"Research and Development\/Global Drug Development, Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Gomez-Caminero","sequence":"additional","affiliation":[{"name":"Worldwide Health Economic and Outcomes Research, Bristol Myers Squibb, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can\u2019t live without.","volume":"191","author":"Azzi","year":"2013","journal-title":"J Immunol"},{"key":"R2-20240805","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity.","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 2","key":"R3-20240805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.13195","article-title":"OPTN\/SRTR 2013 annual data report: kidney.","volume":"15","author":"Matas","year":"2015","journal-title":"Am J Transplant"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1111\/ajt.16463","article-title":"Long-term kidney transplant graft survival-making progress when most needed.","volume":"21","author":"Poggio","year":"2021","journal-title":"Am J Transplant"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R6-20240805","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","article-title":"Summary of the US FDA approval of belatacept.","volume":"12","author":"Archdeacon","year":"2012","journal-title":"Am J Transplant"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"R10-20240805","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation.","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20240805","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept-versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study.","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transplant"},{"key":"R12-20240805","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches.","volume":"10","author":"Abbas","year":"2020","journal-title":"World J Transplant"},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/TP.0b013e318270bc7b","article-title":"Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database.","volume":"94","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2015.08.007","article-title":"Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment.","volume":"369","author":"Petrara","year":"2015","journal-title":"Cancer Lett"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression.","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/TP.0b013e3182007b95","article-title":"An integrated safety profile analysis of belatacept in kidney transplant recipients.","volume":"90","author":"Grinyo","year":"2010","journal-title":"Transplantation"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1177\/2168479018764662","article-title":"The use of real-world evidence and data in clinical research and postapproval safety studies.","volume":"52","author":"Lamberti","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"R20-20240805","first-page":"CD010699","article-title":"Belatacept for kidney transplant recipients.","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","article-title":"Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation.","volume":"86","author":"Neff","year":"2008","journal-title":"Transplantation"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13365-014-0303-1","article-title":"A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.","volume":"21","author":"Chahin","year":"2015","journal-title":"J Neurovirol"},{"key":"R23-20240805","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1681\/ASN.2016070768","article-title":"Comparing outcomes between antibody induction therapies in kidney transplantation.","volume":"28","author":"Koyawala","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R24-20240805","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/00007890-200211150-00014","article-title":"Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors.","volume":"74","author":"Port","year":"2002","journal-title":"Transplantation"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:02:56Z","timestamp":1722816176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001644","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}